Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): A novel case report
Abstract
DIOSD: dupilumab-induced ocular surface disease FDA: US Food and Drug Administration A 37-year-old man with a life-long history of severe atopic dermatitis developed newonset, severe conjunctivitis approximately 3 months after initiating therapy with dupilumab at the standard, US Food and Drug Administration (FDA)-approved dose regimen and was immediately referred to ophthalmology. He had a history of dry eyes but had not required treatment. There was dramatic thickening of the upper and lower lids along with swelling, redness, and injection of the sclera and conjunctiva. Alternative causes such as allergy, foreign body, and infection were ruled out based on ocular findings and history. The diagnoses of conjunctivitis, blepharitis, and dry eyes were made. Visual acuity was normal. At this time, initiated therapy included oral omega 3 supplements, warm compresses, artificial tears, and topical loteprednol drops 4 times a day in both eyes, tapering over several weeks. Six weeks later, the patient reported that his redness and irritation had improved but not completely resolved with this regimen and recurred after stopping the steroids. The patient underwent 2 more courses of treatment with steroid drops, either with loteprednol or fluorometholone, depending on cost. Each time, his symptoms improved but did not resolve and recurred once he stopped the steroids. At his 3-month visit, cyclosporine 0.5% drops were started twice a day in each eye along with another course of…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- eggNOG 5.0: a hierarchical, functionally and phylogenetically annotated orthology resource based on 5090 organisms and 2502 viruses
- Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
- OptiType: precision HLA typing from next-generation sequencing data
- Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications
- Saccharomyces cerevisiae cells have three Omega class glutathione S-transferases acting as 1-Cys thiol transferases
- Hemolysis at low blood flow rates: in-vitro and in-silico evaluation of a centrifugal blood pump
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.